Opium (Opioid) Addiction-Pipeline Review, H2 2017

Opium (Opioid) Addiction-Pipeline Review, H2 2017


  • Products Id :- GMDHC9710IDB
  • |
  • Pages: 114
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Opium (Opioid) Addiction-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Opium (Opioid) Addiction-Pipeline Review, H2 2017, provides an overview of the Opium (Opioid) Addiction (Central Nervous System) pipeline landscape.

Opioid Addiction develops after using opioids regularly for a period of time. Prolonged use of opiates can lead to nerve damage within the brain that causes cells to stop producing endogenous opiates (natural painkillers known as endorphins). This can lead to an inability for the body to stop pain because there are no endorphins to mask the pain initially. The degeneration of the nerve cells that reduce pain can lead to a physical dependence on opiates as an external supply source. Signs and symptoms include increased general anxiety, euphoria, psychosis, depression, high blood pressure, decreased appetite, physical agitation, difficulty sleeping and pain in the bones. The predisposing factors include age, a personal history of substance abuse, and family history of substance abuse, cigarette dependency and psychologic stress.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Opium (Opioid) Addiction-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Opium (Opioid) Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Opium (Opioid) Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 6, 5, 7, 12 and 3 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.

Opium (Opioid) Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Opium (Opioid) Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Opium (Opioid) Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Opium (Opioid) Addiction (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Opium (Opioid) Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Opium (Opioid) Addiction-Overview

Opium (Opioid) Addiction-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Opium (Opioid) Addiction-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Opium (Opioid) Addiction-Companies Involved in Therapeutics Development

Alkermes Plc

Aoxing Pharmaceutical Company Inc

BioCorRx Inc

BioDelivery Sciences International Inc

Camurus AB

Fab'entech SA

Foresee Pharmaceuticals LLC

Indivior Plc

Insys Therapeutics Inc

iX Biopharma Ltd

Nemus Bioscience Inc

Novartis AG

Omeros Corp

Opiant Pharmaceuticals Inc

Orexigen Therapeutics Inc

Orexo AB

Pfizer Inc

Relmada Therapeutics Inc

Teva Pharmaceutical Industries Ltd

Titan Pharmaceuticals Inc

Zynerba Pharmaceuticals Inc

Opium (Opioid) Addiction-Drug Profiles

(buprenorphine hydrochloride + naloxone hydrochloride)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(buprenorphine hydrochloride + naloxone hydrochloride)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(buprenorphine hydrochloride + naloxone hydrochloride)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(buprenorphine hydrochloride + naloxone hydrochloride)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(buprenorphine hydrochloride + samidorphan l-malate)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

18-MC-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANS-6637-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibody for Poisoning, Drug Overdose and Opioid Addiction-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AQU-010-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

buprenorphine hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

buprenorphine hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

buprenorphine hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

buprenorphine hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

buprenorphine hydrochloride depot-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

buprenorphine hydrochloride SR-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

buprenorphine MR-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cannabidiol-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cannabidiol-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Canquit-O-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FP-004-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mavoglurant-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naltrexone hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naltrexone hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naltrexone hydrochloride SR-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NB-2111-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NB-2222-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NT-814-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMS-405-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMS-527-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OREX-1019-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-4363467-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-5006739-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize D3 Receptor for Opioid Addiction-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TEV-90109-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Opioid Addiction-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Opium Addiction-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Opium (Opioid) Addiction-Dormant Projects

Opium (Opioid) Addiction-Discontinued Products

Opium (Opioid) Addiction-Product Development Milestones

Featured News & Press Releases

Sep 01, 2017: Indivior Responds To Court Rulings in ANDA Litigation and Announces Intention To Appeal

Aug 02, 2017: Zubsolv gains preferred position on CVS Caremark 2018 Formulary

Aug 02, 2017: Nemus Bioscience Announces Presentation of NB2111 Analgesic and Anti-Addiction Data at NIH-Sponsored Cannabinoid Conference

Jul 31, 2017: Indivior Announces FDA Acceptance with Priority Review Designation of RBP-6000 Buprenorphine Monthly Depot New Drug Application (NDA) for the Treatment of Opioid Use Disorder

Jul 25, 2017: BioCorRx Announces EnLite Clinics to Implement the BioCorRx Recovery Program in Three Clinics in Ohio

Jul 20, 2017: Braeburn and Camurus Announce Submission of NDA for Long-Acting Buprenorphine (CAM2038) for Opioid Use Disorder

Jul 10, 2017: Orexigen Announces Presentation of Data for OREX-1019, Candidate for the Treatment of Chronic Pain with Reduced Addiction Liability and the Treatment and Management of Opioid Drug Addiction

Jul 06, 2017: BioCorRx to Exhibit at ASAM Conference in Dallas, Texas

Jun 29, 2017: Fortune Article Highlights Titan Pharmaceuticals And Its ProNeura Technology

Jun 29, 2017: Indivior Provides Update on RBP-6000

Jun 22, 2017: Long-acting Buprenorphine Blocks Opioid Effects and Suppresses Withdrawal Symptoms

Jun 21, 2017: Indivior Presents Results from the Phase 3 Pivotal Study of RBP-6000 Buprenorphine Monthly Depot for the Treatment of Opioid Use Disorder

Jun 15, 2017: Braeburn Pharmaceuticals and Camurus Announce Presentations of Pivotal Clinical Study Data of Long-acting Buprenorphine

Jun 13, 2017: Braeburn and Knight Therapeutics Announce Filing of PROBUPHINE in Canada

Jun 06, 2017: TSRI Anti-Heroin Vaccine Found Effective in Non-Human Primates

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Opium (Opioid) Addiction, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

List of Tables

Number of Products under Development for Opium (Opioid) Addiction, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Opium (Opioid) Addiction-Pipeline by Alkermes Plc, H2 2017

Opium (Opioid) Addiction-Pipeline by Aoxing Pharmaceutical Company Inc, H2 2017

Opium (Opioid) Addiction-Pipeline by BioCorRx Inc, H2 2017

Opium (Opioid) Addiction-Pipeline by BioDelivery Sciences International Inc, H2 2017

Opium (Opioid) Addiction-Pipeline by Camurus AB, H2 2017

Opium (Opioid) Addiction-Pipeline by Fab'entech SA, H2 2017

Opium (Opioid) Addiction-Pipeline by Foresee Pharmaceuticals LLC, H2 2017

Opium (Opioid) Addiction-Pipeline by Indivior Plc, H2 2017

Opium (Opioid) Addiction-Pipeline by Insys Therapeutics Inc, H2 2017

Opium (Opioid) Addiction-Pipeline by iX Biopharma Ltd, H2 2017

Opium (Opioid) Addiction-Pipeline by Nemus Bioscience Inc, H2 2017

Opium (Opioid) Addiction-Pipeline by Novartis AG, H2 2017

Opium (Opioid) Addiction-Pipeline by Omeros Corp, H2 2017

Opium (Opioid) Addiction-Pipeline by Opiant Pharmaceuticals Inc, H2 2017

Opium (Opioid) Addiction-Pipeline by Orexigen Therapeutics Inc, H2 2017

Opium (Opioid) Addiction-Pipeline by Orexo AB, H2 2017

Opium (Opioid) Addiction-Pipeline by Pfizer Inc, H2 2017

Opium (Opioid) Addiction-Pipeline by Relmada Therapeutics Inc, H2 2017

Opium (Opioid) Addiction-Pipeline by Teva Pharmaceutical Industries Ltd, H2 2017

Opium (Opioid) Addiction-Pipeline by Titan Pharmaceuticals Inc, H2 2017

Opium (Opioid) Addiction-Pipeline by Zynerba Pharmaceuticals Inc, H2 2017

Opium (Opioid) Addiction-Dormant Projects, H2 2017

Opium (Opioid) Addiction-Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Alkermes Plc

Aoxing Pharmaceutical Company Inc

BioCorRx Inc

BioDelivery Sciences International Inc

Camurus AB

Fab'entech SA

Foresee Pharmaceuticals LLC

Indivior Plc

Insys Therapeutics Inc

iX Biopharma Ltd

Nemus Bioscience Inc

Novartis AG

Omeros Corp

Opiant Pharmaceuticals Inc

Orexigen Therapeutics Inc

Orexo AB

Pfizer Inc

Relmada Therapeutics Inc

Teva Pharmaceutical Industries Ltd

Titan Pharmaceuticals Inc

Zynerba Pharmaceuticals Inc

Opium (Opioid) Addiction Therapeutic Products under Development, Key Players in Opium (Opioid) Addiction Therapeutics, Opium (Opioid) Addiction Pipeline Overview, Opium (Opioid) Addiction Pipeline, Opium (Opioid) Addiction Pipeline Assessment

select a license
Single User License
USD 2000 INR 137580
Site License
USD 4000 INR 275160
Corporate User License
USD 6000 INR 412740

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com